Fabrazyme (agalsidase beta) is a recombinant form of the human enzyme α-galactosidase A, used in the treatment of Fabry disease, a rare genetic disorder. Fabry disease is caused by the buildup of a specific type of fat, globotriaosylceramide (GL-3), in the body's cells, leading to a wide range of symptoms including pain, kidney failure, heart disease, and stroke. Fabrazyme works by replacing the deficient enzyme in patients with Fabry disease, helping to break down GL-3 and prevent its accumulation. Administered through intravenous infusion, Fabrazyme is a form of enzyme replacement therapy that has been shown to improve kidney function, reduce pain, and enhance the quality of life for individuals with this condition.